Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Immunogenicity of DNA vaccines in humans: it takes two to tango.

Lu S.

Hum Vaccin. 2008 Nov-Dec;4(6):449-52. Epub 2008 Nov 28. Review.

PMID:
18443427
2.

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.

Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B.

Vaccine. 2007 Mar 1;25(11):2145-54. Epub 2006 Nov 13.

PMID:
17254672
3.

Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, Swales J, Seaman MS, Combadiere B, Shattock RJ.

J Virol. 2014 Jun;88(12):6959-69. doi: 10.1128/JVI.00183-14. Epub 2014 Apr 9.

4.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

5.

Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost.

Vinner L, Wee EG, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC, Hanke T, Fomsgaard A.

J Gen Virol. 2003 Jan;84(Pt 1):203-13.

PMID:
12533717
6.

Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.

Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

Vaccine. 2015 May 11;33(20):2347-53. doi: 10.1016/j.vaccine.2015.03.036. Epub 2015 Mar 25.

7.

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.

Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur Megede J, Barnett SW.

AIDS. 2004 Apr 30;18(7):991-1001.

PMID:
15096801
8.
9.

Therapeutic and prophylactic DNA vaccines for HIV-1.

Ramirez LA, Arango T, Boyer J.

Expert Opin Biol Ther. 2013 Apr;13(4):563-73. doi: 10.1517/14712598.2013.758709. Review.

PMID:
23477730
10.
11.

Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.

Kumar S, Aggarwal P, Vajpayee M, Pandey RM, Seth P.

Vaccine. 2006 Mar 24;24(14):2585-93. Epub 2006 Jan 4.

PMID:
16480792
12.

Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.

Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Franken KL, Friggen AH, Junginger HE, Borchard G, Klein MR, Ottenhoff TH.

Vaccine. 2009 Jun 19;27(30):4010-7. doi: 10.1016/j.vaccine.2009.04.033. Epub 2009 May 3.

PMID:
19389445
13.

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

Devito C, Zuber B, Schröder U, Benthin R, Okuda K, Broliden K, Wahren B, Hinkula J.

J Immunol. 2004 Dec 1;173(11):7078-89.

14.

Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.

Calarota SA, Weiner DB, Lori F, Lisziewicz J.

Vaccine. 2007 Apr 20;25(16):3070-4. Epub 2007 Jan 22.

PMID:
17292518
15.

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.

Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, Rabussay D, Barnett S, Ulmer JB.

Vaccine. 2006 May 22;24(21):4503-9. Epub 2005 Aug 19.

PMID:
16181711
16.

Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR.

Vaccine. 2010 Nov 23;28(50):7881-9. doi: 10.1016/j.vaccine.2010.09.079. Epub 2010 Oct 23.

PMID:
20937317
17.

Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.

Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley RT, Benson CA.

Clin Vaccine Immunol. 2008 Jun;15(6):986-94. doi: 10.1128/CVI.00492-07. Epub 2008 Apr 9.

18.
20.

Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant.

Sun J, Hou J, Li D, Liu Y, Hu N, Hao Y, Fu J, Hu Y, Shao Y.

Vaccine. 2013 Jan 7;31(3):472-9. doi: 10.1016/j.vaccine.2012.11.024. Epub 2012 Nov 19.

PMID:
23174201

Supplemental Content

Support Center